Previous 10 | Next 10 |
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A sharp market rotation tied to economic reopening caused...
Image source: The Motley Fool. Biomarin Pharmaceutical Inc (NASDAQ: BMRN) Q1 2021 Earnings Call Apr 29, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transc...
The FDA has extended the PDUFA date for BioMarin's (BMRN) short stature treatment vosoritide by three months to November 20, 2021, to review two-year phase 3 data.Data from that extension study presented last month demonstrated the long-term benefit of vosoritide in treating achondr...
BioMarin Pharmaceutical (BMRN): Q1 GAAP EPS of $0.09 beats by $0.19.Revenue of $486M (-3.2% Y/Y) beats by $39.65M.Re-affirms prior guidance of $1.75B-$1.85B vs. $1.82B consensus. Non-GAAP net income of $170M-$220M. Press Release For further details see: BioMarin Pharmaceu...
BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates - Full-year 2021 Financial Guidance Reaffirmed - Total Revenues Grew 9% in the First Quarter 2021 Compared to First Quarter 2020, Excluding Kuvan - Regulatory Actions in Europe for Vosoritide a...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy continued to rebound in what we view as a mo...
BioMarin Pharmaceutical (BMRN) and the Allen Institute announce a collaboration to create new gene therapies aimed at rare genetic diseases of the central nervous system.BioMarin will receive an exclusive license to each program for research, development and commercialization.Financial terms ...
Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases The collaboration leverages technologies intended to target gene expression to specific cells within the central nervous system PR Newswire SEATTLE and SAN RAFAEL, Calif. ,...
Data from a phase 2 extension study of BioMarin's (BMRN) vosoritide for achondroplasia showed improvement in growth velocity was sustained over five years of treatment.The mean increase in annual growth velocity ("AGV") over 60 months of treatment was 1.35 (±1.07) cm/year and mean increa...
BioMarin Pharmaceutical (BMRN) presents updated data on its investigational treatment, vosoritide, in children with achondroplasia, the most common form of skeletal dysplasia leading to disproportionate short stature in humans.The Phase 2 extension study showed that improvement in growth velo...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease PR Newswire Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, C...
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...